Zafirlukast
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00549 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 35 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bronchitis | KG + DL |
| 2 | obstructive lung disease | KG + DL |
| 3 | asthma-related traits, susceptibility to | KG + DL |
| 4 | atopic eczema | KG + DL |
| 5 | uterine polyp | KG + DL |
| 6 | polyp of vocal cord | KG + DL |
| 7 | polyp of middle ear | KG + DL |
| 8 | fibroepithelial polyp | KG + DL |
| 9 | polyp of frontal sinus | KG + DL |
| 10 | polyp of vulva | KG + DL |
| 11 | polyp of ureter | KG + DL |
| 12 | polyp of external auditory canal | KG + DL |
| 13 | neoplastic polyp | KG + DL |
| 14 | epulis | KG + DL |
| 15 | bronchial neoplasm (disease) | KG + DL |
| 16 | Laubry-Pezzi syndrome | KG + DL |
| 17 | laryngotracheitis | KG + DL |
| 18 | interventricular septum aneurysm | KG + DL |
| 19 | nasal cavity polyp | KG + DL |
| 20 | heart disease | KG + DL |
| 21 | genetic syndromic Pierre Robin syndrome | KG + DL |
| 22 | indolent plasma cell myeloma | KG + DL |
| 23 | 2-hydroxyethyl methacrylate sensitization | KG + DL |
| 24 | pulmonary valve disease | KG + DL |
| 25 | Pierre Robin syndrome associated with a chromosomal anomaly | KG + DL |
| 26 | mitral valve disease | KG + DL |
| 27 | orofacial clefting syndrome | KG + DL |
| 28 | partial deletion of the long arm of chromosome 7 | KG + DL |
| 29 | disorder of fucoglycosan synthesis | KG + DL |
| 30 | Jeune syndrome situs inversus | KG + DL |
| 31 | partial deletion of the long arm of chromosome 22 | KG + DL |
| 32 | papillary conjunctivitis | KG + DL |
| 33 | rheumatoid arthritis | KG + DL |
| 34 | plasma cell myeloma | KG + DL |
| 35 | dermatitis, atopic | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.